Mmastodon HealthHealth first seen 2 d ago, last 2 d ago, peak #3

Diabetes drug sitagliptin shows promise in pancreatic cancer trial

Original: In a 22-patient phase 2 trial, adding sitagliptin to gemcitabine and nab-paclitaxel produced a 36.4% response rate. Labo

A 22-patient phase 2 trial found that adding sitagliptin, a common diabetes medication, to the chemotherapy combination gemcitabine and nab-paclitaxel produced a 36.4% response rate in pancreatic cancer patients. Laboratory work points to a possible resistance mechanism, but researchers caution the uncontrolled single-center study cannot establish any survival benefit.

Why now: Early results suggesting a cheap, widely available diabetes drug may boost pancreatic cancer treatment are drawing attention despite the trial's small size.

sitagliptingemcitabinenab-paclitaxelpancreatic cancer

Open on mastodon →

Evidence

• In a 22-patient phase 2 trial, adding sitagliptin to gemcitabine and nab-paclitaxel produced a 36.4% response rate. Laboratory results suggest a possible resistance mechanism, but the uncontrolled single-center study cannot establish a survival benefit. A Diabetes Drug Shows an… · news@newtqnia.com · 2

API: https://socialmediatrends-api.osmike.com/v1/trends/4702446